Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
Impact of Publicly Reported Outcomes on Patient Selection for Hematopoietic Cell Transplantation.
Journal: JCO oncology practice
Published: October 02, 2025
Pemigatinib for Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement.
Journal: NEJM evidence
Published: August 26, 2025
Impact of Public Reporting of Center-Specific Survival Analysis Scores on Patient Volumes at Hematopoietic Cell Transplant Centers.
Journal: Transplantation and cellular therapy
Published: April 20, 2023
Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 22, 2021
Phase 2 Study of Anti-Human Cytomegalovirus Monoclonal Antibodies for Prophylaxis in Hematopoietic Cell Transplantation.
Journal: Antimicrobial agents and chemotherapy
Published: December 16, 2019
Integration of Publicly Reported Center Outcomes into Standards and Accreditation: The FACT Model.
Journal: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
Published: April 26, 2019
Effect of Aging and Predonation Comorbidities on the Related Peripheral Blood Stem Cell Donor Experience: Report from the Related Donor Safety Study.
Journal: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
Published: August 27, 2018
Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at one year compared to unrelated donors.
Journal: Haematologica
Published: June 21, 2018
Improving Outcomes in Chronic Myeloid Leukemia Over Time in the Era of Tyrosine Kinase Inhibitors.
Journal: Clinical lymphoma, myeloma & leukemia
Published: April 05, 2018
Donor Lymphocyte Infusions Used to Treat Mixed-Chimeric and High-Risk Patient Populations in the Relapsed and Nonrelapsed Settings after Allogeneic Transplantation for Hematologic Malignancies Are Associated with High Five-Year Survival if Persistent Full Donor Chimerism Is Obtained or Maintained.
Journal: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
Published: April 21, 2017
Exploratory study on the impact of switching to nilotinib in 18 patients with chronic myeloid leukemia in chronic phase with suboptimal response to imatinib.
Journal: Therapeutic advances in hematology
Published: January 03, 2017
Last Updated: 09/26/2026